Showing 1213 results
- Key Release /Ad hoc announcement pursuant to Art. 53 LR Chinook Therapeutics is a clinical-stage biopharmaceutical company with two high-value, late-stage assets in development for IgA nephropathy (IgAN), a rare…
- Media Release /Survey of Unmet Needs in chronic myeloid leukemia (CML SUN) data signal need for amplified patient voice during treatment discussions that balance quality of life (QoL), efficacy, and tolerability…
- Media Release /Sandoz well positioned to deliver continued mid-single digit sales growth; core EBITDA margin of 24-26% and Free Cash Flow to more than double over mid term European champion committed to…
- Media Release /Kisqali is the first and only CDK4/6 inhibitor to demonstrate a consistent, clinically meaningful benefit across a broad population of patients with HR+/HER2- early breast cancer, regardless of…
- Media Release /Cosentyx® (secukinumab) is the first new biologic treatment for hidradenitis suppurativa (HS) in nearly a decade, offering clinically meaningful results across the most debilitating symptoms1,2…
- Media Release /Sandoz AG to remain based in Basel, Switzerland following proposed spin-off from Novartis Announcement of planned city-center HQ marks important milestone as Sandoz prepares to become independent…
- Media Release /Submissions supported by comprehensive analytical and clinical data package including a Phase I PK/PD similarity study and the integrated Phase I/III ROSALIA clinical trialDenosumab is indicated for…
- Media Release /Novartis Board of Directors approves the recommendation of Sandoz Chairman-designate for the future Sandoz Board of Directors, to start preparatory work in June, followed by formal constitution in H2…
- Media Release /Updated iptacopan data confirm hemolysis control in paroxysmal nocturnal hemoglobinuria (PNH) patients from Phase III APPLY-PNH and APPOINT-PNH studies Head-to-head data from Phase III…
- Media Release /Sandoz and Just - Evotec Biologics announce partnership to develop and manufacture multiple biosimilars with an option for expansion Sandoz gains access to proprietary AI-driven technology platform…